Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
P/S ratio for Sera Prognostics, Inc. (SERA)
P/S ratio as of 2023: 609.74
According to Sera Prognostics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 609.74. At the end of 2022 the company had a P/S ratio of 145.48.
P/S ratio history for Sera Prognostics, Inc. from 2019 to 2023
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2023 | 609.74 |
| 2022 | 145.48 |
| 2021 | 2578.27 |
| 2020 | 14612.77 |
| 2019 | 10147.75 |